The impact of expanded access programs for systemic anticancer therapy in an Irish cancer centre
Open Access
- 28 May 2024
- journal article
- research article
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 193 (5) , 2171-2177
Abstract
Background: Expanded access programs (EAPs) allow cancer patients with unmet clinical need to obtain access to pre-authorisation treatments. There is no standardised process for implementing these programs nationally, and real-world data on their impact is lacking. Aims: This study aimed to evaluate the prevalence of such EAPs and their impact in a cancer centre. Methods: Data relating to adult cancer patients treated via EAPs from 2011 to 2021 in three Cork university hospitals was collated. Descriptive statistics were employed to get an overview of the impact these programs currently have on cancer care provision. Results: We identified 193 patients who accessed EAPs during the study period, availing of 33 separate drugs for a total of 50 different cancer indications. The prevalence of EAP usage was shown to have been trending upwards in recent years with a total of 189 programs being accessed throughout the period. Drugs provided were from a number of different anti-cancer drug classes, particularly targeted therapies (n = 18) and immune checkpoint inhibitors (n = 17). Cancers from a wide range of both solid and liquid tumour types were treated with EAP drugs, and patients treated were from across a broad spectrum of ages (26–82, SD 11.99). Conclusions: EAPs have an increasing role in accessing novel cancer therapies in our community and by extension nationally. Equity of EAP access would be facilitated by a national registry of available agents which we have established. Assessment of their benefits and toxicities would be enhanced by the requirement for a real-world database as a condition of EAP approval.Keywords
All Related Versions
Funding Information
- Breakthrough Cancer Research
- University College Cork
This publication has 16 references indexed in Scilit:
- Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 yearsEuropean Journal of Cancer, 2021
- Understanding the Right to Try ActClinical Cancer Research, 2020
- Physician perspectives on compassionate use in pediatric oncologyPediatric Blood & Cancer, 2018
- Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefitsExpert Opinion on Investigational Drugs, 2018
- Pre-approval Access Terminology: A Cause for Confusion and a Danger to PatientsTherapeutic Innovation & Regulatory Science, 2017
- Expanded Access Programme: looking for a common definitionTrials, 2016
- An overview of Compassionate Use Programs in the European Union member statesIntractable & Rare Diseases Research, 2016
- Early market access of cancer drugs in the EUAnnals of Oncology, 2015
- The changing world of cancer drug development: the regulatory bodies' perspective2014
- Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing?PharmacoEconomics, 2013